Sort   by:  
 Page size 
UnknownSupportive care needs in Australian melanoma patients and caregivers: results from a quantitative cross-sectional survey.
Not available
S-EPMC10624748 | biostudies-literature
MetabolomicsLongitudinal metabolomics and lipidomics analyses reveal markers of envenoming by Bothrops asper and Daboia russelii in an experimental murine model

Longitudinal metabolomics and lipidomics analysis was carried out in the blood plasma of mice injected intramuscularly with venoms of the viperid species Bothrops asper and Daboia russelii. Blood samples were collected 1, 3, 6 and 24 h after venom injection, and a control group ...

2022-09-21 | MTBLS5430 | MetaboLights
UnknownAltering physician referral practices is challenging, but not impossible: spine assessment clinic quality improvement study.
Not available
S-EPMC12496095 | biostudies-literature
UnknownGPNN: power studies and applications of a neural network method for detecting gene-gene interactions in studies of human disease.
Not available
S-EPMC1388239 | biostudies-literature
UnknownRepertoire of bovine miRNA and miRNA-like small regulatory RNAs expressed upon viral infection.
Not available
S-EPMC2713767 | biostudies-literature
UnknownMeasuring axial length of the eye from magnetic resonance brain imaging.
Not available
S-EPMC8817515 | biostudies-literature
UnknownNivolumab and rituximab in treatment-naive follicular lymphoma: the phase 2 1st FLOR study.
Not available
S-EPMC11960644 | biostudies-literature
ProteomicsTumour mtDNA mutations drive aerobic glycolysis to enhance checkpoint blockade (part 2)
Mitochondrial DNA (mtDNA) encodes essential machinery for respiration and metabolic homeostasis but is paradoxically among the most common targets of somatic mutations in the cancer genome, with truncating mutations in complex I genes being over-represented1 . While mtDNA mutations have been associ...
ORGANISM(S): Mus musculus (Mouse) 
2023-11-08 | PXD044987 | Pride
Melanoma Cancer Complex i Mitochondrial dna 
UnknownSingle-Fraction vs Multifraction Stereotactic Ablative Body Radiotherapy for Pulmonary Oligometastases (SAFRON II): The Trans Tasman Radiation Oncology Group 13.01 Phase 2 Randomized Clinical Trial.
Not available
S-EPMC8404145 | biostudies-literature
UnknownRadiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial.
Not available
S-EPMC6269599 | biostudies-literature
Sort   by:  
 Page size